In the present study, we provided evidence supporting previous findings that both fenofibrate (a PPARα agonist) and pioglitazone (a PPARγ agonist) significantly improve insulin sensitivity and glucose tolerance, with fenofibrate exhibiting superior effects in mice fed an HFD. Here, PPARA is linked to glucose measurement.